Capsular contracture

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Endo Announces Publication of New XIAFLEX® (collagenase clostridium histolyticum) Survey Data in Journal of Hand Surgery Global Open

Retrieved on: 
Wednesday, January 24, 2024

DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1

Key Points: 
  • DUBLIN, Jan. 24, 2024 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that the peer-reviewed Journal of Hand Surgery Global Open published Collagenase Clostridium Histolyticum for the Treatment of Dupuytren Disease: A Delphi-Based Consensus Study .1
    Consensus-based study findings among expert hand surgeons indicate that XIAFLEX® (collagenase clostridium histolyticum) has a wide-ranging application for the appropriate treatment of Dupuytren's contracture in patients with varying degrees of disease severity and functional impairment.
  • Results from the published research indicate a high level of consensus for using XIAFLEX for the treatment of one- or two-finger metacarpophalangeal (MP) joint contractures, most one- or two-finger proximal interphalangeal (PIP) joint contractures, and most combined MP and PIP joint contractures.
  • "Healthcare providers and patients can choose among multiple surgical and nonsurgical treatment options for Dupuytren's disease, and without established guidelines, the process for sorting through those choices can be overwhelming," said Dr. Gary M. Pess, a hand and upper extremity surgeon and lead author of the study.
  • "This study provides insight from experienced hand surgeons about using XIAFLEX to treat varying degrees of Dupuytren's contracture."

Global Dupuytren's Disease Market Analysis Report 2023-2030: Adalimumab Emerges as Cost-Effective Treatment for Early-Stage Disease - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023

This projected market expansion highlights the growing recognition of the importance of addressing and treating this condition effectively.

Key Points: 
  • This projected market expansion highlights the growing recognition of the importance of addressing and treating this condition effectively.
  • Consequently, intensified research and development efforts are anticipated in the near future, leading to advancements in treatment options and potential breakthroughs in managing Dupuytren's disease.
  • In a recent study, adalimumab emerged as a potentially cost-effective treatment choice during the early stages of Dupuytren's disease.
  • These results underscore the potential advantages of adalimumab as a practical and economically viable treatment option specifically for individuals in the early stages of Dupuytren's disease.

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren’s Contracture

Retrieved on: 
Wednesday, November 30, 2022

The MHRA reviewed the primary and secondary endpoints in the Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD) trial and the data provided by the Company.

Key Points: 
  • The MHRA reviewed the primary and secondary endpoints in the Repurposing Anti-TNF for Treating Dupuytren's Disease (RIDD) trial and the data provided by the Company.
  • The MHRA also asked for additional literature supporting the clinical safety of adalimumab from other approved indications such as rheumatoid arthritis.
  • However, there is no assurance that such a submission will be timely filed, or favorably received or approved.
  • About 180 Life Sciences Corp.
    180 Life Sciences Corp. is a clinical-stage biotechnology company driving ground-breaking studies into clinical programs which are seeking to address major unmet medical needs.

Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren’s Disease

Retrieved on: 
Tuesday, November 15, 2022

They extrapolated the trial results using a patient-level simulation model, which estimated the lifetime cost-effectiveness of adalimumab for treatment of Dupuytrens Disease.

Key Points: 
  • They extrapolated the trial results using a patient-level simulation model, which estimated the lifetime cost-effectiveness of adalimumab for treatment of Dupuytrens Disease.
  • The researchers simulation found that repeated courses of intranodular injections of adalimumab are likely to be cost-effective for treating progressive early-stage Dupuytrens disease.
  • Lead author, Dr Helen Dakin , University Research Lecturer at Oxford Population Healths Health Economics Research Centre, said: Adalimumab is likely to be a cost-effective treatment for progressive early-stage Dupuytrens disease.
  • Our phase 2b data shows that Adalimumab has the potential to transform the management of progressive early-stage Dupuytrens disease.

California Surgeon is the First to Offer Transumbilical Breast Augmentation with Silicone Implants

Retrieved on: 
Tuesday, June 8, 2021

This left patients desiring the natural, lightweight feel of silicone breast implants with prominent incisions on or near the breasts.

Key Points: 
  • This left patients desiring the natural, lightweight feel of silicone breast implants with prominent incisions on or near the breasts.
  • The addition of the transumbilical incision option for silicone gel-filled implants is a significant milestone in the history of breast augmentation; since attaining FDA approval in 2006, silicone implants have become the preferred implant of hundreds of thousands of breast augmentation patients every year.
  • He has dubbed the technique for placing silicone implants through a transumbilical incision "TUSBA," which stands for "Transumbilical Silicone Breast Augmentation."
  • "Good candidates for TUSBA breast augmentation include non-smokers in good health who want the natural feel of silicone breast implants without visible scarring.

Breast Augmentation Market worth $1,692 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, August 20, 2020

CHICAGO, Aug. 20, 2020 /PRNewswire/ -- According to the new market research report "Breast Augmentation Marketby Product (Silicone Breast Implant, Saline Breast Implant), Shape (Anatomical, Round), Surface (Smooth, Textured), Procedure (Inframammary Fold, Trans-axillary), End User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the global Breast Augmentation Market size is projected to reach USD 1,692 million by 2025 from USD 900 million in 2020, at a CAGR of 13.4%.

Key Points: 
  • CHICAGO, Aug. 20, 2020 /PRNewswire/ -- According to the new market research report "Breast Augmentation Marketby Product (Silicone Breast Implant, Saline Breast Implant), Shape (Anatomical, Round), Surface (Smooth, Textured), Procedure (Inframammary Fold, Trans-axillary), End User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the global Breast Augmentation Market size is projected to reach USD 1,692 million by 2025 from USD 900 million in 2020, at a CAGR of 13.4%.
  • The growth in this market is attributed to the increasing number of breast augmentation procedures and rising awareness of cosmetic surgeries.
  • Based on the product, the market is segmented into silicone breast implant and saline breast implant.
  • In 2019, the silicone breast implant segment accounted for the larger share of the market.

Breast Augmentation Market worth $1,692 million by 2025 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, August 20, 2020

CHICAGO, Aug. 20, 2020 /PRNewswire/ -- According to the new market research report "Breast Augmentation Marketby Product (Silicone Breast Implant, Saline Breast Implant), Shape (Anatomical, Round), Surface (Smooth, Textured), Procedure (Inframammary Fold, Trans-axillary), End User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the global Breast Augmentation Market size is projected to reach USD 1,692 million by 2025 from USD 900 million in 2020, at a CAGR of 13.4%.

Key Points: 
  • CHICAGO, Aug. 20, 2020 /PRNewswire/ -- According to the new market research report "Breast Augmentation Marketby Product (Silicone Breast Implant, Saline Breast Implant), Shape (Anatomical, Round), Surface (Smooth, Textured), Procedure (Inframammary Fold, Trans-axillary), End User, and Region - Global Forecast to 2025", published by MarketsandMarkets,the global Breast Augmentation Market size is projected to reach USD 1,692 million by 2025 from USD 900 million in 2020, at a CAGR of 13.4%.
  • The growth in this market is attributed to the increasing number of breast augmentation procedures and rising awareness of cosmetic surgeries.
  • Based on the product, the market is segmented into silicone breast implant and saline breast implant.
  • In 2019, the silicone breast implant segment accounted for the larger share of the market.

Beverly Hills Plastic Surgeon Innovates Popular Butt Lift Procedure

Retrieved on: 
Wednesday, November 20, 2019

LOS ANGELES, Nov. 20, 2019 /PRNewswire-PRWeb/ -- The Brazilian Butt Lift, also known as BBL surgery, has become quite popular in the past decade but BBL plus 360 Lipo is the new and improved version of BBL surgery according to Dr. William Rahal of Beverly Hills.

Key Points: 
  • LOS ANGELES, Nov. 20, 2019 /PRNewswire-PRWeb/ -- The Brazilian Butt Lift, also known as BBL surgery, has become quite popular in the past decade but BBL plus 360 Lipo is the new and improved version of BBL surgery according to Dr. William Rahal of Beverly Hills.
  • In addition to a larger, more shapely buttock, the patient gets an hourglass figure which enhances the overall result."
  • Dr. William Rahal is a Board Certified Plastic Surgeon located with offices in Beverly Hills, California.
  • His specialties include Brazilian Butt Lift (BBL) with 360 Lipo, Breast Augmentation, Liposuction, Tummy Tuck, Breast Lift, as well as Surgical & Non-Surgical options to treat Capsular Contracture (Breast Implant Complications).

Growth of Breast Implants Market to be Impacted by Rising Number of Breast Cosmetic Procedures | Technavio

Retrieved on: 
Thursday, October 17, 2019

This has increased the number of breast cosmetic procedures such as breast augmentation, breast reduction, and mastopexy among women to enhance breast aesthetic appearance, symmetry, and proportion.

Key Points: 
  • This has increased the number of breast cosmetic procedures such as breast augmentation, breast reduction, and mastopexy among women to enhance breast aesthetic appearance, symmetry, and proportion.
  • These factors are driving the growth of the global breast implants market.
  • Gummy bear breast implants are naturally soft to touch, do not rupture, and retain the implant shape even when the shells get broken.
  • The growing popularity of gummy bear breast implants is expected to boost market growth during the forecast period.